No Photo Available

Last Update

2016-11-30T00:00:00.000Z

This profile was last updated on .

Is this you? Claim your profile.

Wrong John Didsbury?

Dr. John Didsbury

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Background Information

Employment History

NCED

Founder and Chief Executive Officer

T3D Therapeutics Inc

President and Chief Executive Officer

Drug Discovery Center of Innovation

President and Chief Operating Officer

DARA BioSciences , Inc.

President and Chief Executive Officer

Nuada Pharmaceuticals Inc

President

Medgenics Inc

Scientist

Genentech , Inc.

Assistant Professor

Duke University

President and Chief Executive Officer

ChemCodes Inc.

Head of Strategy and Operations for Drug Discovery Unit

GlaxoSmithKline plc

Education

BA

Biology

The University of Connecticut

Bachelor of Arts

biology/chemistry

University of Connecticut

Ph.D.

Ph.D.

Medical Microbiology

University of Vermont Medical College

PhD

Medicinal Microbiology

The University of Vermont College of Medicine

Web References (153 Total References)


A Novel Approach to Alzheimer's Drug Therapy, Phase 2a Clinical Trial Results of T3D-959 to be Presented by T3D Therapeutics at CTAD

www.prweb.com [cached]

John Didsbury, Ph.D., CEO T3D Therapeutics, Inc. 1-919-237-4897

...
John Didsbury T3D Therapeutics, Inc.


nuclear receptors PPAR delta and gamma ...

www.brainmattersresearch.com [cached]

nuclear receptors PPAR delta and gamma to control lipid and energy homeostasis regulating fatty acid oxidation, energy dissipation, and mitochondrial respiration," commented John Didsbury, Ph.D., Chief Executive Officer of T3D Therapeutics.


T3D Therapeutics Announces Presentation of Phase 2a Preliminary Results of T3D-959 in Alzheimer's Subjects at the 2016 Alzheimer's Association International Conference

www.prweb.com [cached]

"T3D-959 is the only Alzheimer's treatment in clinical development of which we are aware that works by dually activating two nuclear receptors PPAR delta and gamma to control lipid and energy homeostasis regulating fatty acid oxidation, energy dissipation, and mitochondrial respiration," commented John Didsbury, Ph.D., Chief Executive Officer of T3D Therapeutics.

...
John Didsbury, Ph.D., CEO T3D Therapeutics, Inc. 1-919-237-4897
...
John Didsbury T3D Therapeutics, Inc.


"This is a significant milestone for ...

www.ncbiotech.org [cached]

"This is a significant milestone for our company," said CEO John Didsbury, a former GlaxoSmithKline executive who took his pharmaceutical company experience into the entrepreneurship realm by founding T3D in 2013.


Commenting on the award, T3D ...

www.prweb.com [cached]

Commenting on the award, T3D Therapeutics' CEO John Didsbury said, "The National Institute on Aging's support will enable us to test our novel approach to developing an Alzheimer's disease drug therapy that has the potential to slow, stop or reverse the progression of disease.

...
John Didsbury T3D Therapeutics, Inc.

Similar Profiles

Other People with this Name

Other people with the name Didsbury

Stephanie Didsbury
Vancouver Island University

Tom Didsbury
Ferguson Financial Ltd

Piccolino Didsbury
Individual Restaurant Company Plc

John Didsbury
Birchall Blackburn LLP

Kimberley Didsbury
SGS SA

City Directory Icon

Browse ZoomInfo's Business Contact Directory by City

People Directory Icon

Browse ZoomInfo's
Business People Directory

Company Directory Icon

Browse ZoomInfo's
Advanced Company Directory